logo
China's plan to boost drug coverage by commercial insurers no ‘magic wand', analysts say

China's plan to boost drug coverage by commercial insurers no ‘magic wand', analysts say

Beijing's plan to publish China's first list of innovative drugs eligible for coverage by commercial health insurance will draw keen interest from pharmaceutical companies, but is not a 'magic wand', as insurers lack sufficient incentives to provide the coverage, analysts said.
The National Healthcare Security Administration, in charge of the state-run basic healthcare insurance scheme, said in a policy document on July 1 that it would publish the list this year, primarily including drugs that were not
covered by state insurance but were highly innovative and provided clear improvements in medical outcomes.
The list would be a 'major attempt to better meet the public's multi-level and diverse drugs demand', said Huang Xinyu, head of the administration's medical services management department, on July 11, as reported by Xinhua.
Both domestic and multinational drug developers will likely be drawn to the initiative, but the same cannot be said of insurers, said Webster Guo, principal at L.E.K. Consulting's China healthcare practice.
'There's likely no harm for drug companies to apply [to have their products included],' he said. 'If you are lagging behind your competitors, the downside could be significant.'
But the situation presented an 'impossible triangle' for insurers, who would struggle to devise products that would achieve national coverage while providing sufficient reimbursement levels at a price that people were willing to pay, he said, because the source of funding was 'not solved'.
Commercial health-insurance payouts of 383.8 billion yuan (US$53.5 billion) in 2023 covered only 6.8 per cent of total direct healthcare costs, while state basic health insurance covered 49.7 per cent and patients paid for 43.5 per cent themselves, according to the Shanghai Insurance Association.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals

South China Morning Post

time40 minutes ago

  • South China Morning Post

GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals

GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. Advertisement The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their product portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The corporate flag of GlaxoSmithKline (GSK) next to a Chinese national flag outside a GlaxoSmithKline office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. Advertisement 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.

Empower Hong Kong's patients with advance care planning
Empower Hong Kong's patients with advance care planning

South China Morning Post

timean hour ago

  • South China Morning Post

Empower Hong Kong's patients with advance care planning

Feel strongly about these letters, or any other aspects of the news? Share your views by emailing us your Letter to the Editor at [email protected] or filling in this Google form . Submissions should not exceed 400 words, and must include your full name and address, plus a phone number for verification Advertisement The Advance Decision on Life-sustaining Treatment Ordinance, which concerns advance medical directives (AMDs) and do-not-attempt cardiopulmonary resuscitation (DNACPR) orders, was passed in late 2024 and will come into operation around mid-2026. Yet public awareness of such advance decisions remains low. Advance care planning (ACP) is needed to facilitate such decisions. It is an empowering process for patients to plan for future healthcare needs while honouring their values and preferences. With the support of healthcare professionals, patients may indicate to family members their preferences for future medical and personal care, especially in scenarios where they are lacking in mental capacity. ACP helps meet the four principles of biomedical ethics in clinical medicine. Advertisement Respect for autonomy is the first principle. ACP provides an informed process to heighten patients' autonomy. After obtaining the necessary information from healthcare professionals, patients may decide on the kinds of healthcare which align with their values and preferences in terms of quality of life during the final journey.

InvestHK at 25: powering growth for global firms in Hong Kong and beyond
InvestHK at 25: powering growth for global firms in Hong Kong and beyond

South China Morning Post

time2 hours ago

  • South China Morning Post

InvestHK at 25: powering growth for global firms in Hong Kong and beyond

When InvestHK was established in July 2000, its mission was clear: attract overseas and mainland Chinese companies to establish or expand in Hong Kong, reinforcing its position as 'Asia's world city'. Twenty-five years on, that mission remains unchanged, but the tools and the scale of support have evolved significantly. Advertisement This year, both InvestHK and Hong Kong Exchanges and Clearing (HKEX) marked their silver jubilees with notable results. In 2024, InvestHK assisted a record 539 mainland Chinese and overseas companies in setting up operations in Hong Kong. Since its establishment in 2000, 145 of InvestHK's clients have listed on HKEX. Between January 2023 and June 2025, InvestHK helped more than 1,300 companies set up or expand in Hong Kong, bringing in over HK$160 billion (US$20 billion) in foreign direct investment. These companies created more than 19,000 jobs in their first year of operation, exceeding the government's 2022 Policy Address targets ahead of schedule. Hong Kong's initial public offering (IPO) market has maintained steady momentum in 2025, with HKEX recording more than 50 listings between January and mid-July, a year-on-year increase of 30 per cent. The exchange ranked first globally in IPO fundraising during the period, with more than 200 companies actively preparing for a public offering in the second half of the year. Support from InvestHK for overseas and mainland Chinese companies and institutions includes planning, setting up and expanding their operations in Hong Kong. The agency provides strategic advice on market entry, practical guidance during the establishment and launch phases, and continued support as businesses grow and scale across international markets via Hong Kong. When an IPO is on the horizon, InvestHK offers pre-listing workshops covering disclosure, environmental, social and governance (ESG), and investor-relations requirements, enabling founders to scale up without needing to shift jurisdictions, a stability that is increasingly valued in an era of geopolitical uncertainty. Advertisement Beyond projects: building ecosystems

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store